Helicore Biopharma

Biotech · Private

Monoclonal antibodies targeting GIP ligand for obesity treatment

helicore.com →
Grants
—
No SBIR or STTR on record
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
5
0 granted · 5 pending
Sector median: 2

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2703EDI THERAPEUTICS LLC——
2704OSEM FLUIDICS INC——
2705Capture Pharmaceuticals, Inc.——
2706Helicore Biopharma——
2707VELAKOR BIOTHERAPEUTICS, INC.——
2708Alltrna——
2709THYREOS, INC——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Patents

USPTO · 0 granted of 5
  • Combinations Of Anti-gip Antibodies And Incretins And Uses Thereofapplication
  • Compositions And Methods For Treating Postural Tachycardia Syndromeapplication
  • Combinations Of Anti-gip Antibodies And Incretins And Uses Thereofapplication
  • Combinations Of Anti-gip Antibodies And Incretins And Uses Thereofapplication
  • Combinations Of Anti-gip Antibodies And Incretins And Uses Thereofapplication

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.